Selon industrie sources on the 24th, companies notamment Yoo-Yu Pharmaceutical, Hanall Biopharma, HLB Therapeutics, RudaCure, and PNP Biopharm have entered the race to develop traitement de la sécheresse oculaires.
Dry eye disease is known to have a very rigorous clinical process and approval criteria. Because it is a condition highly sensitive to environmental factors, it involves more variables than other essais cliniques, and it is also difficult to objectively quantify drug efficacy sur la base de patients' subjective responses.
Nevertheless, no national company has ever succeeded in developing a new drug for this condition, and with the global traitement de la sécheresse oculaire market projected to expand to KRW 12 trillion by 2028, active research is underway.
Bioventure RudaCure is developing traitement de la sécheresse oculaire candidate 'RCI001.' Selon RudaCure, RCI001 devrait demonstrate faster sécrétion lacrymale efficacy and récupération des lésions cornéennes compared to commercially available competing drugs, along with superior instillation compliance and safety. L'entreprise anticipates that the drug will show rapid onset of action while significatifly reducing effets secondaires tels que élévation de la pression intraoculaire.